PARK7

PARK7. PARK7, also known as DJ-1, is a gene that encodes a highly conserved protein with critical roles in cellular protection against oxidative stress and mitochondrial function. Mutations in this gene are a well-established cause of early-onset, autosomal recessive Parkinson's disease. The PARK7 protein functions as a redox-sensitive chaperone and protease, and its loss of function is linked to the pathological accumulation of misfolded proteins and neuronal death characteristic of neurodegeneration.

● Gene and protein structure

The PARK7 gene is located on the short arm of chromosome 1 at locus 1p36.23-p36.12. It consists of eight exons and spans approximately 24 kilobases of genomic DNA. The gene is transcribed into a 1.2 kilobase messenger RNA that is translated into a protein of 189 amino acids with a predicted molecular mass of 20 kDa. The PARK7 protein, DJ-1, belongs to the ThiJ/PfpI superfamily and functions as a homodimer. Its three-dimensional structure, solved by X-ray crystallography, reveals a conserved Rossmann fold and a reactive cysteine residue at position 106 (Cys-106) that is essential for its redox-sensing activity. The protein localizes to the cytoplasm, mitochondria, and nucleus, with its subcellular distribution influenced by cellular stress conditions.

● Function and mechanism

PARK7/DJ-1 performs multifaceted protective functions within the cell. It acts as a sensor for reactive oxygen species through the oxidation of its critical Cys-106 residue, which triggers its translocation to the mitochondria to mitigate oxidative damage. The protein exhibits chaperone activity, preventing the aggregation of misfolded proteins like α-synuclein, a key component of Lewy bodies. Furthermore, DJ-1 regulates mitochondrial dynamics and quality control by interacting with proteins such as PTEN-induced putative kinase 1 and influencing mitophagy. It also modulates transcriptional responses to stress by stabilizing the nuclear factor erythroid 2–related factor 2 transcription factor, thereby upregulating the expression of antioxidant genes. Additional roles include regulation of the phosphatidylinositol 3-kinase/Akt signaling pathway and androgen receptor signaling.

● Role

in disease Biallelic loss-of-function mutations in the PARK7 gene are a confirmed genetic cause of early-onset, autosomal recessive Parkinson's disease. These mutations, which include point mutations, deletions, and splice-site variants, lead to a loss of the protein's protective functions. Pathologically, PARK7-associated Parkinson's disease is characterized by the degeneration of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies. Beyond monogenic Parkinson's disease, oxidative modification and decreased levels of the DJ-1 protein have been observed in the brain and cerebrospinal fluid of patients with the more common sporadic form of Parkinson's disease, as well as in other conditions like Alzheimer's disease and amyotrophic lateral sclerosis. This suggests a broader role for DJ-1 dysfunction in general mechanisms of neurodegeneration.

● Animal models and research

Research utilizing animal models has been instrumental in elucidating the physiological functions of PARK7. Drosophila melanogaster with DJ-1 ortholog mutations exhibit increased sensitivity to paraquat and rotenone, along with locomotor deficits and loss of dopaminergic neurons. Similarly, Caenorhabditis elegans models show disrupted dopamine-dependent behaviors. Mus musculus with a targeted deletion of the PARK7 gene (DJ-1 knockout mice) develop normally but display increased vulnerability to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and deficits in dopamine release and motor coordination with age. These models consistently support the protein's role in mitigating oxidative stress and maintaining mitochondrial integrity, providing a platform for testing potential therapeutic strategies.

● Therapeutic implications

The established role of PARK7/DJ-1 in neuroprotection has made it a compelling target for therapeutic development in Parkinson's disease and related disorders. Strategies aim to either restore or mimic its function. One approach involves the development of small-molecule activators of the nuclear factor erythroid 2–related factor 2 pathway, which DJ-1 normally regulates. Another strategy focuses on identifying compounds that can stabilize the DJ-1 protein or enhance its chaperone activity to prevent α-synuclein aggregation. Gene therapy vectors designed to deliver a functional PARK7 gene to the substantia nigra are also under investigation in preclinical models. Furthermore, because DJ-1 is detectable in cerebrospinal fluid and blood plasma, it is being studied as a potential biomarker for early diagnosis and tracking disease progression in Parkinson's disease. Category:Genes Category:Parkinson's disease